Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 44

Sort by

Sort Order Select

Journal Articles

Risk prediction for clonal cytopenia: multicenter real-world evidence

Blood (2024) 144 (19): 2033–2044.

https://doi.org/10.1182/blood.2024024756

Published: 2024

Includes: Supplemental data

Journal Articles

Paroxysmal nocturnal hemoglobinuria–related thrombosis in the era of novel therapies: a 2043-patient-year analysis

Carmelo Gurnari, Hussein Awada, Simona Pagliuca, Danai Dima, Fauzia Ullah, Naomi Kawashima, Yasuo Kubota, Ceylan Colak, Valeria Visconte, Bhumika J. Patel, Vikram Dhillon, Naimisha Marneni, Suresh Kumar Balasubramanian, Ashwin Kishtagari, Taha Bat, Jaroslaw P. Maciejewski

Blood (2024) 144 (2): 145–155.

https://doi.org/10.1182/blood.2024023988

Published: 2024

Journal Articles

Clonal Hematopoiesis and Inflammation in the Vasculature (CHIVE), a Prospective, Longitudinal Clonal Hematopoiesis Cohort and Biorepository

Blood (2023) 142 (Supplement 1): 5594.

https://doi.org/10.1182/blood-2023-189808

Published: 2023

Journal Articles

Assessing the Impact of Blood Cancer Talks , a Novel ‘how I Treat’ Style Podcast on Hematologic Malignancies: A Survey-Based Analysis

Rajshekhar Chakraborty, Edward R Scheffer Cliff, Ashwin Kishtagari

Blood (2023) 142 (Supplement 1): 7270.

https://doi.org/10.1182/blood-2023-184594

Published: 2023

Journal Articles

Covalent Menin Inhibitor Bmf-219 in Patients with Relapsed or Refractory (R/R) Acute Leukemia (AL): Preliminary Phase 1 Data from the Covalent-101 Study

Blood (2023) 142 (Supplement 1): 2916.

https://doi.org/10.1182/blood-2023-173149

Published: 2023

Journal Articles

Flat Dose Intravenous Immunoglobulin Primary Infection Prophylaxis in Multiple Myeloma Patients on Bispecific Antibody Therapy: Vanderbilt Experience

Naimisha Marneni, Bhagirathbhai Dholaria, Salyka Sengsayadeth, Eden Ayele Biltibo, Vivek Patel, Shakthi Bhaskar, Reena Jayani, Jill Gilbert, Jordan Berlin, Ashwin Kishtagari, Sanjay Mohan, David Morgan, Olalekan O. Oluwole, Bipin N. Savani, Adetola A. Kassim, Muhamed Baljevic

Blood (2023) 142 (Supplement 1): 3778.

https://doi.org/10.1182/blood-2023-190749

Published: 2023

Journal Articles

Platelet Response in Pacritinib-Treated Patients with Cytopenic Myelofibrosis: A Retrospective Analysis of PERSIST-2 and PAC203 Studies

Pankit Vachhani, Abdulraheem Yacoub, Elie Traer, Lina Benajiba, Francesco Passamonti, Ashwin Kishtagari, Mojtaba Akhtari, James McCloskey, Sarah Buckley, Purvi Suthar, Karisse Roman-Torres, John Mascarenhas

Blood (2023) 142 (Supplement 1): 4554.

https://doi.org/10.1182/blood-2023-178725

Published: 2023

Journal Articles

Preliminary Results from a Phase 1 Dose Escalation Study of FHD-286, a Novel BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, Administered As an Oral Monotherapy in Patients with Advanced Hematologic Malignancies

Courtney D. DiNardo, Michael R. Savona, Ashwin Kishtagari, Amir T. Fathi, Kapil N. Bhalla, Samuel Agresta, Sarah Reilly, Caroline Almon, Murphy Hentemann, Denice Hickman, Dillon Corrigan, Meghan Macaraeg, Jessica Piel, Kim Horrigan, Salah Nabhan, Paul Martin, Eytan M. Stein

Blood (2023) 142 (Supplement 1): 4284.

https://doi.org/10.1182/blood-2023-178090

Published: 2023

Journal Articles

Preliminary Results from a Phase 1b Dose De-Escalation Stage of Abnl-Marro 001: An International MDS/MPN Working Group Study

Blood (2023) 142 (Supplement 1): 1874.

https://doi.org/10.1182/blood-2023-181673

Published: 2023

Journal Articles

Selinexor Plus Ruxolitinib in JAK Inhibitor (JAKi)-Naïve Patients with Myelofibrosis: Long Term Follow up from XPORT-MF-034 Suggestive of Disease Modification

Srinivas K. Tantravahi, Ashwin Kishtagari, Keri Maher, Sanjay Mohan, Josef T. Prchal, Xulong Wang, Kamal Chamoun, Christopher J Walker, Pietro Taverna, Haris Ali

Blood (2023) 142 (Supplement 1): 622.

https://doi.org/10.1182/blood-2023-180844

Published: 2023

Journal Articles

Toxicity and Outcomes in Octo- and Nonagenarians with AML Treated with Venetoclax and Hypomethylating Agent Therapy

Blood (2022) 140 (Supplement 1): 3306–3308.

https://doi.org/10.1182/blood-2022-170771

Published: 2022

Journal Articles

A Phase 1, Open-Label, Dose-Escalation Study of Selinexor Plus Ruxolitinib in Patients with Treatment-Naïve Myelofibrosis

Haris Ali, Ashwin Kishtagari, Keri Maher, Sanjay R Mohan, Karen Ansaldo, Xulong Wang, Kamal Chamoun, Josef T. Prchal, Srinivas K. Tantravahi

Blood (2022) 140 (Supplement 1): 3986–3987.

https://doi.org/10.1182/blood-2022-160039

Published: 2022

Journal Articles

The Characteristics and Prognosis of Patients with Clonal Cytopenias of Undetermined Significance, Including Cancer and Therapy-Related Clonal Cytopenias

Blood (2022) 140 (Supplement 1): 2887–2890.

https://doi.org/10.1182/blood-2022-162367

Published: 2022

Journal Articles

Integrating Mosaic Chromosomal Alterations and Single-Nucleotide Variants to Predict Evolution of Clonal Hematopoiesis

Ashwin Kishtagari, MA Wasay Khan, Yajing Li, Cosmin Bejan, Naimisha Marneni, Alexander J. Silver, Kelly von Beck, Travis Spaulding, Shannon Stockton, Christina A. Snider, Kelly Pugh, Andrew Sochacki, Dixon Dorand, Taralynn Mack, Caitlyn Vlasschaert, Brent Ferrell, Yaomin Xu, Michael R. Savona, Alexander G. Bick

Blood (2022) 140 (Supplement 1): 2868–2870.

https://doi.org/10.1182/blood-2022-170957

Published: 2022

Journal Articles

TP53 Mutations Are Associated with Increased Infections and Reduced Hematopoietic Cell Transplantation Rates in Myelodysplastic Syndrome and Acute Myeloid Leukemia

Jennifer Marvin-Peek, Ashwin Kishtagari, Reena Jayani, Bhagirathbhai Dholaria, Tae Kon Kim, Emily F Mason, Brian G. Engelhardt, Heidi Chen, Adetola A. Kassim, Michael R. Savona, Bipin Savani, Michael Byrne

Blood (2022) 140 (Supplement 1): 11638–11640.

https://doi.org/10.1182/blood-2022-164631

Published: 2022

Journal Articles

The similarity of class II HLA genotypes defines patterns of autoreactivity in idiopathic bone marrow failure disorders

Blood (2021) 138 (26): 2781–2798.

https://doi.org/10.1182/blood.2021012900

Published: 2021

Includes: Supplemental data

Journal Articles

Machine learning integrates genomic signatures for subclassification beyond primary and secondary acute myeloid leukemia

Blood (2021) 138 (19): 1885–1895.

https://doi.org/10.1182/blood.2020010603

Published: 2021

Includes: Supplemental data

Journal Articles

Immunogenetic Drivers in Post-Transplant Acute Myeloid Leukemia Recurrence: Genomic Dysfunction of Human Leukocyte Antigen Diversity

Simona Pagliuca, Carmelo Gurnari, Laila Terkawi, Ishani Pandit, Tariq Kewan, Waled Bahaj, Minako Mori, Suresh Kumar Balasubramanian, Ashwin Kishtagari, Hetty E. Carraway, Betty K. Hamilton, Navneet S. Majhail, Valeria Visconte, Jaroslaw P. Maciejewski

Blood (2021) 138 (Supplement 1): 3921.

https://doi.org/10.1182/blood-2021-153577

Published: 2021

Journal Articles

Characteristics and Clinical Outcome of Patients with Clonal Cytopenias of Undetermined Significance: A Large Retrospective Multi-Center International Study

Blood (2021) 138 (Supplement 1): 2158.

https://doi.org/10.1182/blood-2021-146254

Published: 2021

Journal Articles

Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: From Recapitulation/Acquisition of Leukemogenic Hits to Immune Escape Due to Somatic Class I/ II HLA Mutations

Simona Pagliuca, MD, Carmelo Gurnari, MD, Sanghee Hong, MD, Cassandra M Kerr, MS, Sunisa Kongkiatkamon, MD, Hassan Awada, MD, Ashwin Kishtagari, MBBS, Misam Zawit, MBBS, Laila Terkawi, Valeria Visconte, PhD, Eric D. Hsi, MD, Betty K. Hamilton, MD, Hetty E. Carraway, MD MBA, Navneet S. Majhail, MD MS, Jaroslaw P. Maciejewski, MD PhD

Blood (2020) 136 (Supplement 1): 21.

https://doi.org/10.1182/blood-2020-143242

Published: 2020

NARROW

Risk prediction for clonal cytopenia: multicenter real-world evidence

Paroxysmal nocturnal hemoglobinuria–related thrombosis in the era of novel therapies: a 2043-patient-year analysis

Clonal Hematopoiesis and Inflammation in the Vasculature (CHIVE), a Prospective, Longitudinal Clonal Hematopoiesis Cohort and Biorepository

Assessing the Impact of Blood Cancer Talks , a Novel ‘how I Treat’ Style Podcast on Hematologic Malignancies: A Survey-Based Analysis

Covalent Menin Inhibitor Bmf-219 in Patients with Relapsed or Refractory (R/R) Acute Leukemia (AL): Preliminary Phase 1 Data from the Covalent-101 Study

Flat Dose Intravenous Immunoglobulin Primary Infection Prophylaxis in Multiple Myeloma Patients on Bispecific Antibody Therapy: Vanderbilt Experience

Platelet Response in Pacritinib-Treated Patients with Cytopenic Myelofibrosis: A Retrospective Analysis of PERSIST-2 and PAC203 Studies

Preliminary Results from a Phase 1 Dose Escalation Study of FHD-286, a Novel BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, Administered As an Oral Monotherapy in Patients with Advanced Hematologic Malignancies

Preliminary Results from a Phase 1b Dose De-Escalation Stage of Abnl-Marro 001: An International MDS/MPN Working Group Study

Selinexor Plus Ruxolitinib in JAK Inhibitor (JAKi)-Naïve Patients with Myelofibrosis: Long Term Follow up from XPORT-MF-034 Suggestive of Disease Modification

Toxicity and Outcomes in Octo- and Nonagenarians with AML Treated with Venetoclax and Hypomethylating Agent Therapy

A Phase 1, Open-Label, Dose-Escalation Study of Selinexor Plus Ruxolitinib in Patients with Treatment-Naïve Myelofibrosis

The Characteristics and Prognosis of Patients with Clonal Cytopenias of Undetermined Significance, Including Cancer and Therapy-Related Clonal Cytopenias

Integrating Mosaic Chromosomal Alterations and Single-Nucleotide Variants to Predict Evolution of Clonal Hematopoiesis

TP53 Mutations Are Associated with Increased Infections and Reduced Hematopoietic Cell Transplantation Rates in Myelodysplastic Syndrome and Acute Myeloid Leukemia

The similarity of class II HLA genotypes defines patterns of autoreactivity in idiopathic bone marrow failure disorders

Machine learning integrates genomic signatures for subclassification beyond primary and secondary acute myeloid leukemia

Immunogenetic Drivers in Post-Transplant Acute Myeloid Leukemia Recurrence: Genomic Dysfunction of Human Leukocyte Antigen Diversity

Characteristics and Clinical Outcome of Patients with Clonal Cytopenias of Undetermined Significance: A Large Retrospective Multi-Center International Study

Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: From Recapitulation/Acquisition of Leukemogenic Hits to Immune Escape Due to Somatic Class I/ II HLA Mutations

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only